Surgery is the first-line treatment of patients with clinically non-functioning pituitary adenomas (NFAs) Because of lack of clinical syndrome these tumours are diagnosed with a variable delay, when patients suffer from compression symptoms (hypopituitarism, headache and visual field defects) due to the extension of the tumour outside the pituitary fossa. Surgery is followed by residual tumour tissue in most patients. In these cases, radiotherapy is generally used to prevent tumour regrowth. However, NFA cell membranes, in analogy with GH- and PRL-secreting adenomas, express somatostatin and dopamine receptors. Treatment with somatostatin analogues (SSA) and dopamine agonists (DA) induced some beneficial effects on visual field defects and was also followed by tumour shrinkage in a minority of cases. DA seem to be more effective on tumour shrinkage than SSA. More recently, a combination treatment with both SSA and DA have been tested in a few patients with interesting results. Lack of randomized, placebo-controlled trials prevents any conclusion on the efficacy of these drugs. By contrast, use of gonatotrophin-releasing hormone analogues has been abandoned.

Medical therapy for clinically non-functioning pituitary adenomas / Colao, Annamaria; Di Somma, Carolina; Pivonello, Rosario; Faggiano, Antongiulio; Lombardi, Gaetano; Savastano, Silvia. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 15:4(2008), pp. 905-915. [10.1677/ERC-08-0181]

Medical therapy for clinically non-functioning pituitary adenomas

Pivonello, Rosario;Faggiano, Antongiulio;
2008

Abstract

Surgery is the first-line treatment of patients with clinically non-functioning pituitary adenomas (NFAs) Because of lack of clinical syndrome these tumours are diagnosed with a variable delay, when patients suffer from compression symptoms (hypopituitarism, headache and visual field defects) due to the extension of the tumour outside the pituitary fossa. Surgery is followed by residual tumour tissue in most patients. In these cases, radiotherapy is generally used to prevent tumour regrowth. However, NFA cell membranes, in analogy with GH- and PRL-secreting adenomas, express somatostatin and dopamine receptors. Treatment with somatostatin analogues (SSA) and dopamine agonists (DA) induced some beneficial effects on visual field defects and was also followed by tumour shrinkage in a minority of cases. DA seem to be more effective on tumour shrinkage than SSA. More recently, a combination treatment with both SSA and DA have been tested in a few patients with interesting results. Lack of randomized, placebo-controlled trials prevents any conclusion on the efficacy of these drugs. By contrast, use of gonatotrophin-releasing hormone analogues has been abandoned.
2008
non-functioning pituitary adenomas;
01 Pubblicazione su rivista::01a Articolo in rivista
Medical therapy for clinically non-functioning pituitary adenomas / Colao, Annamaria; Di Somma, Carolina; Pivonello, Rosario; Faggiano, Antongiulio; Lombardi, Gaetano; Savastano, Silvia. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 15:4(2008), pp. 905-915. [10.1677/ERC-08-0181]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1675387
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 130
social impact